RFK Advisors Advance Landmark Overhaul of Childhood Vaccination Policies

RFK advisors push for sweeping overhaul of U.S. childhood vaccine policies

Health secretary’s handpicked panel proposes ending universal newborn hepatitis B shots and reexamining the childhood schedule for allergy and timing concerns.

Federal vaccine advisers appointed by Health Secretary Robert F. Kennedy Jr. are preparing to pursue what could be the most sweeping changes to the United States childhood immunization program in decades, with proposals that include ending the universal hepatitis B shot at birth and creating a broad review of whether timing, ingredients or combinations of childhood vaccines contribute to rising rates of allergies and autoimmune disorders.

The Advisory Committee on Immunization Practices (ACIP), now chaired by a Kennedy appointee, has signaled that members will vote this week on whether to delay or stop recommending the hepatitis B vaccine for most newborns — a reversal of a policy in place for decades intended to protect infants from a virus that can cause chronic liver disease. The committee is also forming a new workgroup to scrutinize the timing and order of routine childhood shots and to review vaccine ingredients, steps that supporters say restore individual informed consent and skeptics warn could erode long-standing, evidence-based protections.

That reorientation follows several earlier ACIP moves under the Kennedy administration: the panel has already voted to limit use of certain combined vaccines for very young children and recommended an antibody product for infant RSV under narrowly defined circumstances — decisions that illustrate the new committee’s willingness to revisit established practice. Public-health groups including the American Academy of Pediatrics have publicly pushed back, warning that decades of data support current childhood schedules and that sudden policy shifts could increase risk from preventable diseases.

Critics — including many infectious disease specialists and some former CDC officials — say the changes appear driven more by political priorities than by broad scientific consensus, noting that several CDC staff experts and outside specialists have been sidelined from the committee’s deliberations and workgroups. Supporters argue the committee is correcting past overreach and restoring a focus on individualized risk–benefit conversations between clinicians and parents.

Federal regulatory agencies are also responding. An internal FDA review and subsequent staff commentary have called for more demanding approval standards and more rigorous evidence of disease-prevention benefits for vaccines administered during pregnancy or infancy — a development likely to shape how any ACIP changes are implemented in practice. Meanwhile, congressional Democrats and public health organizations have publicly urged caution and called for transparent evidence before upending longstanding recommendations.

As ACIP prepares to vote, clinicians, hospitals, and state immunization programs face uncertainty about implementation timelines and the practical effects on hospital newborn protocols and school-entry requirements. Whatever the vote’s outcome, the deliberations mark a major shift in U.S. vaccine policymaking that could reshape pediatric preventive care and rekindle intense national debate over vaccines and public health.

Sources and links

• The Washington Post
•  Reuters
• The Guardian
• Fierce Pharma
• Axios
• STAT
• CIDRAP
• CDC
• Forbes